Scarica l'app Stockscreener
75.49
0.97%
-0.74
Dopo l'orario di chiusura:
76.21
0.72
+0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$76.23
Aprire:
$76.06
Volume 24 ore:
594.48K
Relative Volume:
0.39
Capitalizzazione di mercato:
$6.06B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-12.71
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+3.31%
1M Prestazione:
-3.91%
6M Prestazione:
+68.73%
1 anno Prestazione:
+63.86%
Intervallo 1D:
$74.90
$77.09
Intervallo di 1 settimana:
$72.56
$77.55
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
75.49 | 6.12B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Sector Gamma AS Increases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Avoiding Lag: Real-Time Signals in (PTCT) Movement - Stock Traders Daily
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Insider Monkey
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
A Look At PTC Therapeutics (PTCT) Valuation As 2026 Revenue Guidance Reshapes Market Expectations - Sahm
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
PTC Therapeutics reports $92.5M in Q4 Sephience revenue - Investing.com
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
PTC Therapeutics Reports Preliminary 2025 Product Revenue, Sets 2026 Product Revenue Guidance - marketscreener.com
Ptc Therapeutics provides update at J.P. Morgan annual healthcare conference - marketscreener.com
Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference - TradingView — Track All Markets
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - Yahoo Finance
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate - Chartmill
PTC Therapeutics, Inc. $PTCT Shares Purchased by SG Americas Securities LLC - MarketBeat
Market Outlook: Will PTC Therapeutics Inc stock sustain high P E ratios2025 EndofYear Setup & Expert Approved Trade Ideas - moha.gov.vn
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup - Chartmill
Is PTC Therapeutics Inc. stock a safe haven assetEarnings Risk Report & Growth Focused Stock Pick Reports - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $49,742.16 in Stock - MarketBeat
Neil Gregory Almstead Sells 1,026 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 3,016 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,279 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells $95,650.75 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 4,879 Shares of Stock - MarketBeat
Stop Loss: Is GDRX stock vulnerable to regulatory risksBuy Signal & Daily Momentum Trading Reports - moha.gov.vn
PTC Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
What dividend safety score for PTC Therapeutics Inc. stockQuarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating - marketscreener.com
PTC THERAPEUTICS, INC. (PTCT) - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):